Irwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan
Back

2 Psychedelic Stocks Thats Are Flying Under The Radar

Jan 26, 2021 • 5:03 PM EST
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

From the easing of regulations to the reporting of positive clinical trial data, the psychedelic sector is a rapidly evolving industry that is starting to show serious signs of legitimacy.

We believe the biggest potential catalyst for the psychedelic sector would be the reporting of positive data from Phase 3 FDA clinical trials. Although this is one of the most exciting aspects of the psychedelic sector, the industry is comprised of variety of burgeoning verticals and we have been focused on identifying potential industry leaders.

PULL Is One To Be Watching

We believe that Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (OTC: PRXTF) represents a differentiated opportunity and are favorable on the leverage that it has to both the cannabis and the psychedelic industry.

Last week, the Company reported a major milestone and saying it has delineated the timetable and milestones for its study with the Toronto Institute of Pharmaceutical Technology (TIPT). The study will focus on formulating, manufacturing, and clinical bioavailability testing of rapid onset psilocybin dosage forms and we are bullish on the potential that is associated with it.

The study will conform to both Canadian Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards. If successful, the psilocybin dosage forms could be used in future efficacy clinical trials by both Pure Extracts and its pharmaceutical customers. We believe the study and the relationship with TIPT are attractive pillars of the Pure Extracts’ story and will monitor how it advances from here.

During the last month, Pure Extracts has reported a number of important developments and is an opportunity to be aware. From the addition of strategic human capital to the strengthening of the balance sheet, we believe the story has recorded impressive advancements and consider Pure Extracts to be an underappreciated opportunity at current levels.

Numinus Has Really Hit Its Stride Over The Past Month

The last month has been volatile for Numinus Wellness Inc. (TSXV: NUMI) (OTC: LKYSF) and this is an operator that we have been following since inception. The company is focused on creating an ecosystem of health solutions that are centered around developing and supporting the use of psychedelic-assisted psychotherapies (PAP).

Last week, health and wellness company reported to have entered into a lab services agreement with Optimi Health Corporation to conduct additional research on the development of psilocybin-producing mushrooms that are grown in Canada. We consider Optimi to be a strategic partner and are favorable on the expertise that it brings to the relationship

Optimi is a vertically integrated functional mushroom brand that is focused on the health and wellness sector. According to the agreement, Optimi will utilize and leverage Numinus’ laboratories, equipment, services and expertise, to develop products for the emerging psychedelic industry. Optimi has applied for a research exemption with Health Canada that would allow for it to conduct activities involving psychedelic compounds. Once the exemption is granted, the companies plan to work on projects with Numinus that are related to psychedelic compounds and formulations.

During the last year, we have seen a significant increase in the amount of demand for natural products that optimize mental health and performance. Numinus’ state-of-the art laboratory and expertise will play a key role in the development of effective all-natural products and will monitor how the relationship advances from here.

Under the terms of the agreement, Optimi will pay an initial retainer to Numinus for services that will be determined and replenished on a project-by-project basis. The agreement represents a milestone for Numinus since it will be the first opportunities for it to generate revenue from independent parties and we expect to see Numinus to enter into additional agreements in the near future.

If you are interested in learning more about the advancement of the psychedelic sector, please send an email to support@mushroomstocks.com with the subject “Psychedelic Sector” to be added to our distribution list.

 

 

 

 

 

 

 

 

 

 

 

 

Pursuant to an agreement between StoneBridge Partners LLC and Pure Extracts Technologies Corp. we have been hired for a period of 180 days beginning November 1, 2020 and ending May 1, 2020 to publicly disseminate information about (PULL) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (PULL) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own one hundred seventy six thousand eight hundred and twenty nine (176,829) shares of (PULL), which we purchased via private placement. We plan to sell the “ZERO” shares of (PULL) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (PULL) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link